Meropenem AptaPharma: Uses, Dosage & Side Effects

What Is Meropenem AptaPharma and What Is It Used For?

Meropenem AptaPharma contains the active substance meropenem, a synthetic carbapenem antibiotic that represents one of the most potent classes of antimicrobial agents available in modern medicine. Carbapenems are a subclass of beta-lactam antibiotics distinguished by their exceptionally broad spectrum of antibacterial activity and their stability against most bacterial beta-lactamase enzymes, including the extended-spectrum beta-lactamases (ESBLs) and AmpC cephalosporinases that confer resistance to many other beta-lactam antibiotics such as penicillins and cephalosporins.

Meropenem exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs) located on the inner surface of the bacterial cell membrane. These PBPs are enzymes critical to the synthesis of peptidoglycan, the structural component of the bacterial cell wall. By inhibiting PBPs, meropenem disrupts cell wall synthesis, leading to osmotic instability, cell lysis, and ultimately bacterial death. Meropenem has a particularly high affinity for PBP2, PBP3, and PBP4 in Escherichia coli and Pseudomonas aeruginosa, which contributes to its broad-spectrum activity including against difficult-to-treat Gram-negative pathogens.

Unlike some other carbapenems (such as imipenem), meropenem is stable against the renal enzyme dehydropeptidase-I (DHP-I) and therefore does not require co-administration with a DHP-I inhibitor such as cilastatin. This simplifies its formulation and administration. After intravenous administration, meropenem distributes rapidly into body tissues and fluids, including peritoneal fluid, bile, lung tissue, bronchial secretions, and cerebrospinal fluid (CSF) in patients with inflamed meninges. This excellent tissue penetration is particularly important for the treatment of meningitis, where adequate CSF concentrations of the antibiotic are essential for clinical success.

The pharmacokinetics of meropenem are characterized by a relatively short elimination half-life of approximately 1 hour in patients with normal renal function. The drug is primarily eliminated by renal excretion, with approximately 70% of a dose recovered unchanged in the urine. This short half-life necessitates frequent dosing, typically every 8 hours. In clinical practice, extended infusion strategies (infusing over 3 hours rather than the standard 30 minutes) are increasingly used to optimize the time-dependent pharmacodynamic profile of meropenem, potentially improving clinical outcomes in critically ill patients.

Meropenem AptaPharma is approved by regulatory authorities including the European Medicines Agency (EMA) for the treatment of the following infections in adults and children aged 3 months and older:

• Complicated intra-abdominal infections: Including peritonitis, intra-abdominal abscesses, and biliary tract infections caused by susceptible organisms. These are among the most common indications for meropenem, particularly when polymicrobial infection involving both aerobic and anaerobic bacteria is suspected.
• Bacterial meningitis: Meropenem is one of the few antibiotics that achieves therapeutically effective concentrations in the cerebrospinal fluid when the meninges are inflamed. It is recommended by international guidelines as empirical therapy for bacterial meningitis, especially when resistant organisms such as penicillin-resistant pneumococci or third-generation cephalosporin-resistant Gram-negative bacilli are suspected.
• Hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP): These infections are frequently caused by multidrug-resistant Gram-negative organisms, and meropenem provides reliable empirical coverage while culture results are pending.
• Complicated skin and soft tissue infections: Including necrotizing fasciitis and polymicrobial wound infections that require broad-spectrum parenteral antibiotic therapy.
• Complicated urinary tract infections: Including pyelonephritis caused by ESBL-producing organisms that are resistant to first-line antibiotic therapy.
• Febrile neutropenia: Meropenem is widely used as empirical monotherapy in febrile neutropenic patients (those with cancer whose white blood cell counts are dangerously low due to chemotherapy), where rapid broad-spectrum coverage is critical to survival.

What Should You Know Before Taking Meropenem AptaPharma?

Contraindications

Before treatment with meropenem is initiated, clinicians must carefully evaluate the patient for absolute contraindications. The primary contraindication is a known hypersensitivity to meropenem, any other carbapenem antibiotic, or any of the excipients in the formulation. Although the risk of cross-reactivity between carbapenems and other beta-lactam antibiotics (penicillins and cephalosporins) is low, patients with a confirmed history of severe immediate-type hypersensitivity (anaphylaxis) to any beta-lactam should receive meropenem only with extreme caution and appropriate monitoring.

Large observational studies and meta-analyses have consistently demonstrated that the cross-reactivity rate between penicillins and carbapenems is approximately 1% or less, which is significantly lower than the historical estimates that were based on older, less pure carbapenem formulations. Nevertheless, caution is warranted in patients with a documented history of anaphylaxis to penicillins or cephalosporins, and skin testing may be considered before initiating meropenem in these individuals.

Warnings and Precautions

Several important warnings and precautions should be considered before and during treatment with meropenem:

• Clostridioides difficile-associated diarrhea (CDAD): As with virtually all antibiotics, meropenem disrupts the normal intestinal flora and may lead to overgrowth of Clostridioides difficile, a toxin-producing bacterium that causes antibiotic-associated diarrhea and colitis. CDAD has been reported with the use of nearly all antibacterial agents, including meropenem, and may range in severity from mild diarrhea to fatal pseudomembranous colitis. If CDAD is suspected or confirmed, meropenem should be discontinued and appropriate treatment initiated.
• Renal impairment: Because meropenem is primarily eliminated by the kidneys, dose adjustments are necessary in patients with moderate to severe renal impairment (creatinine clearance <51 mL/min) and in patients receiving hemodialysis. Failure to adjust the dose may result in drug accumulation, increasing the risk of seizures and other CNS adverse events.
• Hepatobiliary effects: Meropenem may cause hepatic dysfunction, including elevated transaminases, alkaline phosphatase, lactate dehydrogenase, and bilirubin. Liver function tests should be monitored periodically during treatment, particularly in patients with pre-existing hepatic disease.
• Thrombocytopenia: Decreases in platelet count have been reported with meropenem. Blood counts should be monitored, especially during prolonged treatment courses.
• Superinfection: Prolonged use of meropenem may result in overgrowth of non-susceptible organisms, including fungi. Patients should be monitored for signs of superinfection, and appropriate measures taken if this occurs.

Pregnancy and Breastfeeding

There are limited data on the use of meropenem in pregnant women. Animal reproduction studies have not revealed evidence of teratogenicity or harm to the fetus at clinically relevant doses. However, as with all medications, meropenem should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus. The decision to use meropenem in pregnancy should be made on a case-by-case basis, taking into account the severity of the infection and the availability of alternative treatments.

Meropenem is excreted in breast milk in small amounts. The effect on breastfed infants has not been adequately studied. A decision must be made whether to discontinue breastfeeding or to withhold meropenem therapy, taking into account the importance of the drug to the mother. The low oral bioavailability of meropenem suggests that systemic absorption by the infant from breast milk would be minimal, but diarrhea and fungal colonization of the mucous membranes in the infant are theoretical concerns that should be monitored.

How Does Meropenem AptaPharma Interact with Other Drugs?

Drug interactions are an important consideration when prescribing meropenem, particularly in critically ill patients who are often receiving multiple medications simultaneously. The most significant and potentially dangerous interaction involves valproic acid, but several other interactions warrant clinical attention.

Major Interactions

Minor Interactions

Meropenem has relatively few pharmacokinetic interactions because it does not undergo significant metabolism by cytochrome P450 enzymes. It is not expected to induce or inhibit the activity of CYP450 isoforms, which limits its potential for interactions with drugs metabolized by these pathways. However, clinicians should remain vigilant for pharmacodynamic interactions, particularly in critically ill patients receiving complex medication regimens.

Meropenem may interfere with certain laboratory tests. It can cause a false-positive reaction in urinary glucose tests that use cupric sulfate (Benedict’s solution or Clinitest tablets). Glucose testing in patients receiving meropenem should use enzymatic glucose oxidase methods instead. Additionally, in rare cases, meropenem may interfere with the direct Coombs test, potentially causing a false-positive result.

What Is the Correct Dosage of Meropenem AptaPharma?

The dosage of meropenem is determined by the type and severity of the infection, the patient’s renal function, body weight (in children), and the susceptibility of the causative organism. Meropenem is administered intravenously, either as a bolus injection over approximately 5 minutes or as an intravenous infusion over 15 to 30 minutes. Extended infusions over 3 hours are also employed in some clinical settings to optimize pharmacodynamic exposure.

Adults

The maximum recommended dose for adults is 2 g every 8 hours (6 g per day). In practice, the higher doses (2 g every 8 hours) are typically reserved for the most serious infections, such as meningitis, nosocomial pneumonia, and infections in critically ill patients. For less severe infections, 500 mg or 1 g every 8 hours is usually adequate.

Children

In children aged 3 months and older, the dosage of meropenem is calculated based on body weight. The recommended dose ranges from 10 mg/kg to 40 mg/kg every 8 hours, depending on the infection type and severity:

For children weighing more than 50 kg, the adult dosing regimen should be used. The safety and efficacy of meropenem in neonates and infants under 3 months of age have not been established, and use in this population is based on limited data and clinical judgment.

Elderly

No specific dose adjustment is required for elderly patients with normal renal function. However, renal function declines with age, and many elderly patients have reduced creatinine clearance even when serum creatinine appears normal. Renal function should be assessed (using calculated creatinine clearance or estimated glomerular filtration rate) before initiating meropenem in elderly patients, and dose adjustments made according to the renal impairment guidelines below.

Missed Dose

Since meropenem is administered in a hospital setting by healthcare professionals, missed doses are rare. However, if a dose is delayed, it should be given as soon as possible, and the regular dosing schedule should be resumed. The interval between the delayed dose and the next dose should be adjusted to maintain the every-8-hour dosing frequency. Consistent dosing is particularly important for meropenem because it is a time-dependent antibiotic, meaning that its bactericidal efficacy depends on the duration of time that plasma concentrations remain above the minimum inhibitory concentration (MIC) of the infecting organism.

Overdose

Intentional overdose with meropenem is unlikely given the intravenous route of administration in a supervised medical setting. However, accidental overdose can occur, particularly in patients with renal impairment whose dose has not been appropriately adjusted. Symptoms of overdose may include nausea, vomiting, diarrhea, and potentially central nervous system effects such as seizures.

There is no specific antidote for meropenem overdose. Treatment is supportive and symptomatic. Meropenem is removed by hemodialysis, which may be considered in cases of severe overdose with significant symptoms. In patients with normal renal function, the short half-life of meropenem (approximately 1 hour) means that plasma concentrations will decrease rapidly once the infusion is stopped.

What Are the Side Effects of Meropenem AptaPharma?

Like all antibiotics, meropenem can cause side effects, although not everyone experiences them. Clinical trials and post-marketing surveillance have identified a range of adverse reactions associated with meropenem therapy. The frequency and severity of side effects can be influenced by the dose, duration of treatment, the patient’s underlying health conditions, and concomitant medications.

The following side effect frequency grid is based on data from clinical trials and the approved Summary of Product Characteristics (SmPC). Frequency categories follow the standard convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), and rare (<1/1,000).

The gastrointestinal side effects (diarrhea, nausea, vomiting) are the most frequently reported adverse reactions and are typically mild to moderate in severity. They are related to the disruption of the normal intestinal microbiome that occurs with all broad-spectrum antibiotics. In most cases, these symptoms resolve spontaneously after discontinuation of meropenem.

Injection site reactions are relatively common with intravenous administration and can be minimized by using appropriate infusion techniques and rotating infusion sites. Thrombophlebitis (inflammation of the vein at the injection site) may occur, particularly with prolonged peripheral intravenous access.

Central nervous system effects, including seizures, are an important safety concern with all carbapenem antibiotics. The risk of seizures with meropenem is generally considered to be lower than with imipenem-cilastatin, which is one of the reasons meropenem is preferred for the treatment of CNS infections such as meningitis. Nevertheless, seizures have been reported and are more likely in patients with renal impairment (due to drug accumulation), pre-existing CNS pathology, or when higher-than-recommended doses are used.

How Should You Store Meropenem AptaPharma?

Proper storage of meropenem is essential to maintain its potency and safety. Meropenem AptaPharma is supplied as a sterile powder in glass vials that require reconstitution before use. The storage requirements differ between the unopened powder and the reconstituted solution.

Unopened vials: Store below 30°C. Keep the vials in the original packaging to protect from light. Do not freeze. The shelf life of the unopened product is stated on the packaging and is typically 3 years from the date of manufacture when stored correctly.

Reconstituted solution: After reconstitution with sterile water for injection or compatible intravenous fluids (such as 0.9% sodium chloride), the solution should ideally be used immediately. If immediate use is not possible, the reconstituted solution may be stored at room temperature (up to 25°C) for up to 3 hours, or under refrigeration (2–8°C) for up to 12 hours. After removal from refrigeration, the solution should be used within 3 hours. Reconstituted solutions should not be frozen.

The reconstituted solution should be a clear, colorless to pale yellow solution. Do not use the product if the solution is cloudy, contains visible particles, or has changed color beyond pale yellow. Any unused solution should be discarded in accordance with hospital pharmacy procedures and local regulations for the disposal of pharmaceutical waste.

Keep all medicines out of the sight and reach of children. Do not dispose of medicines via household waste or wastewater. Ask your pharmacist about how to properly dispose of medicines that are no longer needed, to help protect the environment.

What Does Meropenem AptaPharma Contain?

Understanding the composition of a medication is important for identifying potential allergens and understanding its pharmaceutical properties. Meropenem AptaPharma has a simple formulation consisting of the active ingredient and a single excipient.

Active ingredient: Each vial contains meropenem trihydrate equivalent to 2,000 mg (2 g) of meropenem. Meropenem trihydrate is the crystalline form of the active substance that provides optimal stability in the powder state. Upon reconstitution, meropenem trihydrate dissolves to release the active meropenem molecule.

Excipient: Anhydrous sodium carbonate (Na₂CO₃) is included as a pH-adjusting agent. When the powder is reconstituted with sterile water or saline, the sodium carbonate buffers the solution to an appropriate pH range (approximately 7.3–8.3) that ensures both the stability of the meropenem molecule and compatibility with intravenous administration. Patients on sodium-restricted diets should be aware that each 2 g vial contains approximately 182 mg (7.9 mmol) of sodium, which may be relevant for patients requiring strict sodium management.

Pharmaceutical form: White to pale yellow sterile powder for solution for injection/infusion. The powder should be reconstituted immediately before use according to the instructions provided in the product information. Compatible diluents include sterile water for injection, 0.9% sodium chloride injection, and 5% dextrose injection.